Epstein-Barr virus (EBV) is the first human tumor virus discovered and is strongly implicated
in the etiology of multiple lymphoid and epithelial cancers. Each year EBV associated …

Different immunotherapeutic approaches have proved to be of significant clinical value to
many patients with different types of advanced cancer. However, we need more precise …

Nasopharyngeal carcinoma (NPC) is a metastasis-prone malignancy closely associated
with the Epstein–Barr virus (EBV). Despite ubiquitous infection of EBV worldwide, NPC …

EBV is a prevalent virus, infecting> 90% of the world's population. This is an oncogenic virus
that causes~ 200,000 cancer-related deaths annually. It is, in addition, a significant …

Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer.
Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been …

Engineering T cells to express chimeric antigen receptors (CARs) specific for antigens on
hematological cancers has yielded remarkable clinical responses, but with solid tumors …

Immunotherapy is one of the most promising and innovative approaches to treat cancer, viral
infections, and other immune-modulated diseases. Adoptive immunotherapy using gene …

The Epstein–Barr virus (EBV) is associated with lymphomas and carcinomas. For some of
these, the adoptive transfer of EBV specific T cells has been therapeutically explored, with …

Background: Adoptive transfer of genetically engineered T-cells to express antigen-specific
T-cell receptor (TCR) is a feasible and effective therapeutic approach for numerous types of …

Epstein-Barr virus (EBV) is a ubiquitous human tumor virus associated with various
malignancies, including B-lymphoma, NK and T-lymphoma, and epithelial carcinoma. It …